Medicamen Biotech Ltd
Thu 21/08/2025,15:47:19 | NSE : MEDICAMEQ
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 361.50
Previous Close
₹ 357.90
Volume
18713
Mkt Cap ( Rs. Cr)
₹492.06
High
₹ 372.55
Low
₹ 355.55
52 Week High
₹ 630.00
52 Week Low
₹ 342.00
Book Value Per Share
₹ 159.80
Dividend Yield
0.27
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Medicamen Biotech Ltd
Your Vote -
Buy
60.00%
Hold
0.00%
Sell
40.00%
60.00%
5 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Medicamen Biotech Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Medicamen Biotec - Copy of Newspaper Publication
-
Medicamen Biotec - Announcement under Regulation 30 (LODR)-Change in Management
-
Medicamen Biotec - Business Responsibility and Sustainability Reporting (BRSR)
-
Medicamen Biotec - Change in Management
-
Medicamen Biotec - Record Date
-
Medicamen Biotec - Outcome of Board Meeting
-
Medicamen Biotec - Integrated Filing- Financial
-
Medicamen Biotec - Outcome of Board Meeting
-
Medicamen Biotec - Outcome of Board Meeting
-
Medicamen Biotec Q1 net profit down 27.43% at Rs 1.64 cr
-
Medicamen Biotec - Outcome Of The Board Meeting Held On August 12, 2025
-
Medicamen Biotec - Board Meeting Intimation for For Consideration And Approval Of Unaudited Financial Results For The Quarter
-
Medicamen Biotec - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Medicamen Biotec - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Medicamen Biotec has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Medicamen Biotec - Trading Window-XBRL
-
Medicamen Biotec - Trading Window
-
Medicamen Biotec - General Updates
-
Medicamen Biotec - Copy of Newspaper Publication
-
Medicamen Biotec - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Medicamen Biotec - Outcome of Board Meeting-XBRL
-
Medicamen Biotec Q4 net profit down 22.26% at Rs 2.41 cr
-
Medicamen Biotec - Dividend
-
Medicamen Biotec - Outcome of Board Meeting
-
Medicamen Biotec - Financial Results Year Ended On 31.03.2025
-
Medicamen Biotec - Board Meeting Intimation
-
Medicamen Biotec - Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange
-
Medicamen Biotech receives ANDA approval from the USFDA for Bortezomib Injection
-
Medicamen Biotech signs CDMO contract with XGX Pharm
Key fundamentals
Evaluate the intrinsic value of Medicamen Biotech Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 244.6001 | 238.792 | 217.9787 | 172.3863 | 151.6863 |
| Liabilities | 244.6001 | 238.792 | 217.9787 | 172.3863 | 151.6863 |
| Equity | 12.7146 | 12.7146 | 12.6511 | 12.2166 | 12.2166 |
| Gross Profit | 16.5566 | 25.9708 | 24.1468 | 23.5554 | 19.5808 |
| Net Profit | 9.4591 | 13.298 | 15.002 | 14.9064 | 12.4866 |
| Cash From Operating Activities | -2.0088 | -0.2462 | -3.4985 | 4.8102 | 13.2862 |
| NPM(%) | 6.24 | 7.71 | 10.88 | 12.91 | 11.33 |
| Revenue | 151.4633 | 172.3862 | 137.884 | 115.4452 | 110.1465 |
| Expenses | 134.9067 | 146.4154 | 113.7372 | 91.8898 | 90.5656 |
| ROE(%) | 4.36 | 6.13 | 6.92 | 6.87 | 5.76 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 1 | 10 | 0.28 | 428.2 | |
| 19 Sep 2024 | 1 | 10 | 0.28 | 506.95 |
| 20 Sep 2023 | 1 | 10 | 0.28 | 781.95 |
| 19 Sep 2022 | 1 | 10 | 0.28 | 607.05 |
Peers
Other companies within the same industry or sector that are comparable to Medicamen Biotech Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 811.90 | -0.52 | 73.61 | 204.89 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 89.90 | 3.82 | 290.00 | 746.59 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 12.53 | -1.03 | 417.67 | 384.82 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 819.35 | -1.00 | 0.00 | 704.05 | -604.77 | 0.00 |
Company Info
MBL was incorporated as a public limited company under the Companies Act, 1956, on December 22, 1993. The certificate of commencement of business was obtained on January 31, 1994. The company has jointly been promoted by Mr.V.Kumar, Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and Mr.Ranjit Singh. MBL is engaged in marketing of various drugs in the domestic and export markets. Company is procuring drugs from various reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba, Purepharma, Oboi Labs etc. and exporting to countries like Germany, Russia, Holland, CIS (Confederation of Independent States) etc. part from domestic ethical and institutional sales. MBL has obtained permission for production of tablets, capsules and liquid orals under loan licence basis from Delhi Drug Control Authority and Madhya Pardesh Drug Control Authority on Welbeck Pharmaceutical Private Limited, New Delhi and Pure Pharma Private Limited, Indore respectively. 2010 -The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share) -The Company appointed Mr. B.K.Gupta as Managing Director. 2011 -The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan. 2013 -Ms. Harshita Sharma has been appointed as Additional Director of the company. 2016 -Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd. 2019 -FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant. 2020 -Global API Facility started Dahej API Plant. 2021 -Operations started Haridwar formulation Unit II(FDF). 2023 --Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections. 2024 -Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. -Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.
MBL was incorporated as a public limited company under the Companies Act, 1956, on December 22, 1993. The certificate of commencement of business was obtained on January 31, 1994. The company has jointly been promoted by Mr.V.Kumar, Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and Mr.Ranjit Singh. MBL is engaged in marketing of various drugs in the domestic and export markets. Company is procuring drugs from various reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba, Purepharma, Oboi Labs etc. and exporting to countries like Germany, Russia, Holland, CIS (Confederation of Independent States) etc. part from domestic ethical and institutional sales. MBL has obtained permission for production of tablets, capsules and liquid orals under loan licence basis from Delhi Drug Control Authority and Madhya Pardesh Drug Control Authority on Welbeck Pharmaceutical Private Limited, New Delhi and Pure Pharma Private Limited, Indore respectively. 2010 -The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share) -The Company appointed Mr. B.K.Gupta as Managing Director. 2011 -The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan. 2013 -Ms. Harshita Sharma has been appointed as Additional Director of the company. 2016 -Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd. 2019 -FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant. 2020 -Global API Facility started Dahej API Plant. 2021 -Operations started Haridwar formulation Unit II(FDF). 2023 --Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections. 2024 -Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. -Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.
Read More
Parent Organisation
Medicamen Biotech Ltd.
Founded
22/12/1993
Managing Director
Mr.Rahul Bishnoi
NSE Symbol
MEDICAMEQEQ
FAQ
The current price of Medicamen Biotech Ltd is ₹ 362.75.
The 52-week high for Medicamen Biotech Ltd is ₹ 372.55 and the 52-week low is ₹ 355.55.
The market capitalization of Medicamen Biotech Ltd is currently ₹ 492.06. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Medicamen Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Medicamen Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Medicamen Biotech Ltd shares.
The CEO of Medicamen Biotech Ltd is Mr.Rahul Bishnoi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
